Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.92 CAD | +0.61% | -1.80% | +24.56% |
Apr. 08 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
Mar. 14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.56% | 114M | |
+12.11% | 68.18B | |
+5.78% | 25.78B | |
+4.48% | 7.99B | |
-2.79% | 7.88B | |
-23.97% | 7.62B | |
+20.68% | 4.45B | |
-4.23% | 3.89B | |
-4.05% | 3.82B | |
+23.62% | 3.69B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Brief: Obtains Public Reimbursement for Vascepa in New Brunswick and with other Public Payors